دورية أكاديمية
أعرض في EDS

Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.

التفاصيل البيبلوغرافية
العنوان: Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.
المؤلفون: Molica P; Division of Endocrinology, Universidade Federal de São Paulo, UNIFESP-EPM, Rua Pedro de Toledo 910, 04039-002, São Paulo, Brazil. patmolica@gmail.com, Nascif SO, Correa-Silva SR, de Sá LB, Vieira JG, Lengyel AM
المصدر: Pituitary [Pituitary] 2010 Dec; Vol. 13 (4), pp. 315-23.
نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: United States NLM ID: 9814578 Publication Model: Print Cited Medium: Internet ISSN: 1573-7403 (Electronic) Linking ISSN: 1386341X NLM ISO Abbreviation: Pituitary Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Norwell, MA : Kluwer Academic Publishers, 1998-
مواضيع طبية MeSH: Adrenocorticotropic Hormone/*blood , Ghrelin/*therapeutic use , Growth Hormone/*blood , Growth Hormone-Releasing Hormone/*therapeutic use , Hydrocortisone/*blood , Oligopeptides/*therapeutic use , Thyrotoxicosis/*drug therapy, Adult ; Anti-Inflammatory Agents/therapeutic use ; Female ; Hormones/therapeutic use ; Humans ; Male ; Thyrotoxicosis/blood
مستخلص: In thyrotoxicosis GH responses to stimuli are diminished and the hypothalamic-pituitary-adrenal axis is hyperactive. There are no data on ghrelin or GHRP-6-induced GH, ACTH and cortisol release in treated hyperthyroidism. We, therefore, evaluated these responses in 10 thyrotoxic patients before treatment and in 7 of them after treatment. GHRH-induced GH release was also studied. Peak GH (μg/L; mean ± SE) values after ghrelin (22.6 ± 3.9), GHRP-6 (13.8 ± 2.3) and GHRH (4.9 ± 0.9) were lower in hyperthyroidism before treatment compared to controls (ghrelin: 67.6 ± 19.3; GHRP-6: 25.4 ± 2.7; GHRH: 12.2 ± 2.8) and did not change after 6 months of euthyroidism (ghrelin: 32.7 ± 4.7; GHRP-6: 15.6 ± 3.6; GHRH: 7.4 ± 2.3), although GH responses to all peptides increased in ~50% of the patients. In thyrotoxicosis before treatment ACTH response to ghrelin was two fold higher (107.4 ± 26.3) than those of controls (54.9 ± 10.3), although not significantly. ACTH response to GHRP-6 was similar in both groups (hyperthyroid: 44.7 ± 9.0; controls: 31.3 ± 7.9). There was a trend to a decreased ACTH response to ghrelin after 3 months of euthyroidism (35.6 ± 5.3; P = 0.052), but after 6 months this decrease was non-significant (50.7 ± 14.0). After 3 months ACTH response to GHRP-6 decreased significantly (20.4 ± 4.2), with no further changes. In hyperthyroidism before treatment, peak cortisol (μg/dL) responses to ghrelin (18.2 ± 1.2) and GHRP-6 (15.9 ± 1.4) were comparable to controls (ghrelin: 16.4 ± 1.6; GHRP-6: 13.5 ± 0.9) and no changes were seen after treatment. Our results suggest that the pathways of GH release after ghrelin/GHRP-6 and GHRH are similarly affected by thyroid hormone excess and hypothalamic mechanisms of ACTH release modulated by ghrelin/GHSs may be activated in this situation.
References: Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1085-90. (PMID: 18505442)
Front Neuroendocrinol. 2004 Apr;25(1):27-68. (PMID: 15183037)
Clin Endocrinol (Oxf). 1995 Nov;43(5):583-9. (PMID: 8548943)
Lancet. 1983 Jul 16;2(8342):119-24. (PMID: 6134978)
Endocr Rev. 1997 Oct;18(5):621-45. (PMID: 9331545)
Science. 1996 Aug 16;273(5277):974-7. (PMID: 8688086)
J Clin Endocrinol Metab. 2001 Feb;86(2):881-7. (PMID: 11158061)
Eur J Endocrinol. 2000 Mar;142(3):231-5. (PMID: 10700716)
Biochem Biophys Res Commun. 2001 Jun 15;284(3):660-6. (PMID: 11396952)
Endocrinology. 2004 Aug;145(8):3731-8. (PMID: 15087428)
Endocrinology. 1997 Nov;138(11):4552-7. (PMID: 9348177)
Clin Endocrinol (Oxf). 1993 May;38(5):515-22. (PMID: 8330446)
J Neuroendocrinol. 1999 Jul;11(7):521-8. (PMID: 10444309)
Acta Endocrinol (Copenh). 1990 Dec;123(6):613-8. (PMID: 2284886)
J Clin Endocrinol Metab. 1971 Apr;32(4):571-4. (PMID: 4926258)
Endocrinology. 1984 May;114(5):1537-45. (PMID: 6714155)
J Clin Endocrinol Metab. 1966 Nov;26(11):1257-60. (PMID: 5924285)
J Clin Endocrinol Metab. 2003 Jul;88(7):3450-3. (PMID: 12843202)
J Clin Endocrinol Metab. 1995 Mar;80(3):942-7. (PMID: 7883854)
Nature. 1999 Dec 9;402(6762):656-60. (PMID: 10604470)
Pituitary. 2007;10(1):27-33. (PMID: 17410412)
J Clin Endocrinol Metab. 1973 Jun;36(6):1162-74. (PMID: 4706204)
J Endocrinol Invest. 2003 Aug;26(8):733-7. (PMID: 14669827)
J Clin Endocrinol Metab. 1974 Apr;38(4):634-7. (PMID: 4820664)
J Endocrinol Invest. 1989 Sep;12(8):517-21. (PMID: 2512339)
Clin Endocrinol (Oxf). 1999 Oct;51(4):461-7. (PMID: 10583313)
J Clin Endocrinol Metab. 1991 Jan;72(1):108-15. (PMID: 1986009)
Neuroendocrinology. 2002 Nov;76(5):316-24. (PMID: 12457042)
Eur J Endocrinol. 2005 Jul;153(1):177-85. (PMID: 15994759)
Endocrinology. 1997 Jun;138(6):2559-68. (PMID: 9165049)
Endocrinology. 1990 Mar;126(3):1374-9. (PMID: 1968379)
Biochem Biophys Res Commun. 1995 Dec 26;217(3):1087-93. (PMID: 8554561)
Horm Metab Res. 2003 Aug;35(8):455-9. (PMID: 12953161)
Bull N Y Acad Med. 1977 Apr;53(3):241-59. (PMID: 266410)
Clin Endocrinol (Oxf). 1991 Aug;35(2):141-4. (PMID: 1934529)
Endocrinology. 1991 May;128(5):2567-76. (PMID: 1850357)
J Neuroendocrinol. 2001 Mar;13(3):275-8. (PMID: 11207942)
J Clin Endocrinol Metab. 1993 Jul;77(1):281-5. (PMID: 8325953)
J Clin Endocrinol Metab. 1996 Apr;81(4):1343-6. (PMID: 8636330)
J Endocrinol. 1996 Feb;148(2):371-80. (PMID: 8699151)
Clin Endocrinol (Oxf). 2001 Dec;55(6):797-803. (PMID: 11895222)
J Clin Endocrinol Metab. 2007 May;92(5):1693-6. (PMID: 17327382)
Braz J Med Biol Res. 1990;23(3-4):293-6. (PMID: 2094541)
Pituitary. 2009;12(4):315-21. (PMID: 19396632)
J Clin Endocrinol Metab. 1966 May;26(5):545-9. (PMID: 4287159)
Endocrinology. 1996 Feb;137(2):418-24. (PMID: 8593784)
J Clin Endocrinol Metab. 1994 Jan;78(1):169-73. (PMID: 8288700)
Endocrinology. 2001 Jun;142(6):2649-59. (PMID: 11356716)
J Clin Endocrinol Metab. 2001 Mar;86(3):1169-74. (PMID: 11238504)
Brain Res Mol Brain Res. 1997 Aug;48(1):23-9. (PMID: 9379845)
J Clin Endocrinol Metab. 1969 Mar;29(3):346-51. (PMID: 5773069)
J Clin Endocrinol Metab. 1999 Jul;84(7):2489-95. (PMID: 10404825)
المشرفين على المادة: 0 (Anti-Inflammatory Agents)
0 (Ghrelin)
0 (Hormones)
0 (Oligopeptides)
4H7N4I6X6A (growth hormone releasing hexapeptide)
9002-60-2 (Adrenocorticotropic Hormone)
9002-72-6 (Growth Hormone)
9034-39-3 (Growth Hormone-Releasing Hormone)
WI4X0X7BPJ (Hydrocortisone)
تواريخ الأحداث: Date Created: 20100706 Date Completed: 20110207 Latest Revision: 20211020
رمز التحديث: 20221213
DOI: 10.1007/s11102-010-0238-3
PMID: 20602173
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7403
DOI:10.1007/s11102-010-0238-3